Can a ginkgo pill soothe both chest pain and depression?
NCT ID NCT04529148
First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time
Summary
This trial tests whether adding ginkgo biloba dropping pills to standard heart treatment can reduce chest pain episodes and improve quality of life in people with stable angina and depression. About 74 adults aged 18 to 75 with coronary heart disease and depressive symptoms will receive either ginkgo biloba or a placebo, alongside their usual care. Researchers will track angina frequency and scores on heart-related quality-of-life questionnaires to see if the herbal supplement offers extra benefit.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Ginkgo biloba dropping pills
- What this could lead to
- If effective, ginkgo biloba could become a complementary treatment to standard care for people with stable angina and depression, potentially improving their quality of life and reducing chest pain episodes.
- What could go wrong
- This is a small, early-stage trial, so results may not apply broadly. Ginkgo biloba can interact with blood thinners and other medications, and its benefit over standard care alone is unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
74 people
The number who actually took part.
- Started
-
Nov 2020
- Finished
-
Aug 2022
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. 18 to 75 years , regardless of gender; 2. Clearly understand and voluntarily participate in the study, and sign the informed consent form; 3. In accordance with the diagnosis of coronary heart disease, and the following diagnostic criteria meet at least one of the following criteria: ① have a clear history of myocardial infarction; ② have accept the treatment of coronary artery revascularization; ③ coronary radiography or coronary angiography results show that at least one coronary artery stenosis and lumen stenosis ≥ 50%; ④ cardiac magnetic resonance imaging or radionuclide myocardial perfusion imaging or cardiac color Doppler diagnosis Coronary heart disease with myocardial ischemia; 4. Consistent with the diagnosis of stable angina pectoris; 5. Stable angina pectoris has been treated according to the clinical guidelines and has been stable for at least 4 weeks; 6. Meet the diagnostic criteria for depressive episode in 《the international statistical classification of diseases and related health problems (ICD-10)》 issued by the World Health Organization; 7. In the past 7 days, have not used any food that has an impact on intestinal flora, such as foods containing probiotics (such as yogurt) or drugs (such as antibiotics). Exclusion Criteria: 1. Acute myocardial events, unstable angina pectoris, severe heart failure; serious arrhythmia; severe or poorly controlled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg); sitting blood pressure and systolic blood pressure ≤ 85 MmHg or symptomatic hypotension, severe primary diseases such as liver, kidney and hematopoietic system, or serious diseases affecting their survival (such as tumor, etc.); 2. Serious suicidal tendency; Hamilton Depression Scale item 3 ≥ 3; bipolar disorder depressive episode in patients with epilepsy history, or depression secondary to other mental or physical diseases; alcohol and drug dependence within one year; 3. Abnormal liver and kidney function (ALT and / or AST \> 3 times of the upper normal limit, and / or CRE \> 2 times of the upper normal limit); 4. Patients who are currently taking anti anxiety drugs; 5. Pregnant women, lactating women, women of childbearing age who do not take effective contraceptive measures, or who plan to conceive during the trial, and whose pregnancy test results are positive before the test; 6. Those who have participated in clinical trials of other new drugs within 30 days before screening; 7. Other reasons the researcher thinks it is not suitable to participate in the experiment; 8. Those with allergic constitution are allergic to the ingredients contained in Ginkgo biloba dropping pills;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Stable angina pectoris associated with depression are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Foshan Chancheng Central Hospital
Foshan, Guangdong, China
-
Shenzhen Luohu District People's Hospital
Shenzhen, Guangdong, China
-
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, Guangdong, China
-
The Second Affiliated Hospital of Guizhou University of Chinese Medicine
Guiyang, Guizhou, China